-
1
-
-
0035901090
-
Inflammation and cancer: Back to Virchow
-
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
-
(2001)
Lancet
, vol.357
, pp. 539-545
-
-
Balkwill, F.1
Mantovani, A.2
-
2
-
-
0014887939
-
The concept of immunological surveillance
-
Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27
-
(1970)
Prog. Exp. Tumor. Res.
, vol.13
, pp. 1-27
-
-
Burnet, F.M.1
-
3
-
-
0037180757
-
Inflammation and cancer
-
DOI 10.1038/nature01322
-
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7 (Pubitemid 36019639)
-
(2002)
Nature
, vol.420
, Issue.6917
, pp. 860-867
-
-
Coussens, L.M.1
Werb, Z.2
-
4
-
-
44649112492
-
Immunotherapy for lung cancer
-
DOI 10.1097/JTO.0b013e318174e9a7, PII 0124389420080600100014
-
Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S164-70 (Pubitemid 351786751)
-
(2008)
Journal of Thoracic Oncology
, vol.3
, Issue.6 SUPPL. 2
-
-
Bradbury, P.A.1
Shepherd, F.A.2
-
5
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
-
(2010)
Int. J. Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
-
6
-
-
14944385553
-
Global cancer statistics 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
-
(2005)
CA Cancer J. Clin.
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
8
-
-
63149173595
-
Trends in lung cancer death rates in belgium and the Netherlands: A systematic analysis of temporal patterns
-
Van Hemelrijck MJ, Kabir Z, Connolly GN. Trends in lung cancer death rates in Belgium and The Netherlands: a systematic analysis of temporal patterns. J Community Health 2009;34:188-94
-
(2009)
J. Community Health
, vol.34
, pp. 188-194
-
-
Van Hemelrijck, M.J.1
Kabir, Z.2
Connolly, G.N.3
-
9
-
-
0346996535
-
Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries
-
DOI 10.1016/j.ejca.2003.08.005
-
Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer 2004;40:96-125 (Pubitemid 37542323)
-
(2004)
European Journal of Cancer
, vol.40
, Issue.1
, pp. 96-125
-
-
Bray, F.1
Tyczynski, J.E.2
Parkin, D.M.3
-
10
-
-
57349182464
-
Annual report to the nation on the status of cancer 1975 - 2005 featuring trends in lung cancer tobacco use and tobacco control
-
Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975 - 2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94
-
(2008)
J. Natl. Cancer Inst.
, vol.100
, pp. 1672-1694
-
-
Jemal, A.1
Thun, M.J.2
Ries, L.A.3
-
11
-
-
0027210487
-
Polychemotherapy in advanced non small cell lung cancer: A meta-analysis
-
DOI 10.1016/0140-6736(93)91882-M
-
Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21 (Pubitemid 23183916)
-
(1993)
Lancet
, vol.342
, Issue.8862
, pp. 19-21
-
-
Souquet, P.J.1
Chauvin, F.2
Boissel, J.P.3
Cellerino, R.4
Cormier, Y.5
Ganz, P.A.6
Kaasa, S.7
Pater, J.L.8
Quoix, E.9
Rapp, E.10
Tumarello, D.11
Williams, J.12
Woods, B.L.13
Bernard, J.P.14
-
12
-
-
77956181367
-
Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death
-
Navaratnam S, Kliewer EV, Butler J, et al. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-15
-
(2010)
Lung Cancer
, vol.70
, pp. 110-115
-
-
Navaratnam, S.1
Kliewer, E.V.2
Butler, J.3
-
13
-
-
0027464958
-
Heterogeneity of mucin gene expression in normal and neoplastic tissues
-
Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51 (Pubitemid 23059449)
-
(1993)
Cancer Research
, vol.53
, Issue.3
, pp. 641-651
-
-
Ho, S.B.1
Niehans, G.A.2
Lyftogt, C.3
Pei Sha Yan4
Cherwitz, D.L.5
Gum, E.T.6
Dahiya, R.7
Kim, Y.S.8
-
14
-
-
2042497140
-
Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung
-
DOI 10.1309/U4WG-E9EB-FJN6-CM8R
-
Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-53 (Pubitemid 38533996)
-
(2004)
American Journal of Clinical Pathology
, vol.121
, Issue.5
, pp. 644-653
-
-
Awaya, H.1
Takeshima, Y.2
Yamasaki, M.3
Inai, K.4
-
15
-
-
0035370711
-
The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature
-
DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
-
Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82 (Pubitemid 32476360)
-
(2001)
Cancer
, vol.91
, Issue.11
, pp. 1973-1982
-
-
Rahn, J.J.1
Dabbagh, L.2
Pasdar, M.3
Hugh, J.C.4
-
16
-
-
0027234998
-
Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene
-
Ding L, Lalani EN, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17
-
(1993)
Cancer Immunol. Immunother
, vol.36
, pp. 9-17
-
-
Ding, L.1
Lalani, E.N.2
Reddish, M.3
-
17
-
-
18444395585
-
x antigens in colorectal adenocarcinoma
-
DOI 10.1046/j.1365-2559.2002.01389.x
-
Baldus SE, Monig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002;40:440-9 (Pubitemid 34535444)
-
(2002)
Histopathology
, vol.40
, Issue.5
, pp. 440-449
-
-
Baldus, S.E.1
Monig, S.P.2
Hanisch, F.-G.3
Zirbes, T.K.4
Flucke, U.5
Oelert, S.6
Zilkens, G.7
Madejczik, B.8
Thiele, J.9
Schneider, P.M.10
Holscher, A.H.11
Dienes, H.P.12
-
18
-
-
17844402226
-
Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes
-
DOI 10.1054/bjoc.2000.1744
-
Kontani K, Taguchi O, Narita T, et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001;84:1258-64 (Pubitemid 32511345)
-
(2001)
British Journal of Cancer
, vol.84
, Issue.9
, pp. 1258-1264
-
-
Kontani, K.1
Taguchi, O.2
Narita, T.3
Izawa, M.4
Hiraiwa, N.5
Zenita, K.6
Takeuchi, T.7
Murai, H.8
Miura, S.9
Kannagi, R.10
-
19
-
-
15644365913
-
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients
-
Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-71 (Pubitemid 28423725)
-
(1998)
Journal of Clinical Pathology
, vol.51
, Issue.9
, pp. 667-671
-
-
Guddo, F.1
Giatromanolaki, A.2
Koukourakis, M.I.3
Reina, C.4
Vignola, A.-M.5
Chlouverakis, G.6
Hilkens, J.7
Gatter, K.C.8
Harris, A.L.9
Bonsignore, G.10
-
20
-
-
34247854880
-
A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer
-
PII 0124389420060100000010
-
Nagai S, Takenaka K, Sonobe M, et al. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006;1:46-51 (Pubitemid 47164020)
-
(2006)
Journal of Thoracic Oncology
, vol.1
, Issue.1
, pp. 46-51
-
-
Nagai, S.1
Takenaka, K.2
Sonobe, M.3
Ogawa, E.4
Wada, H.5
Tanaka, F.6
-
21
-
-
0034789572
-
Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer
-
Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57; discussion 58 (Pubitemid 32904315)
-
(2001)
Clinical Lung Cancer
, vol.3
, Issue.1
, pp. 49-57
-
-
Palmer, M.1
Parker, J.2
Modi, S.3
Butts, C.4
Smylie, M.5
Meikle, A.6
Kehoe, M.7
MacLean, G.8
Longenecker, M.9
-
22
-
-
70349416505
-
Vaccines for the treatment of non-small cell lung cancer: A renewed anticancer strategy
-
Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009;14:909-20
-
(2009)
Oncologist
, vol.14
, pp. 909-920
-
-
Gridelli, C.1
Rossi, A.2
Maione, P.3
-
23
-
-
33744546327
-
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy
-
DOI 10.1016/S0022-5347(06)00494-0, PII S0022534706004940
-
North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006;176:91-5 (Pubitemid 43815368)
-
(2006)
Journal of Urology
, vol.176
, Issue.1
, pp. 91-95
-
-
North, S.A.1
Graham, K.2
Bodnar, D.3
Venner, P.4
-
24
-
-
33947224631
-
MUC1 is a novel regulator of ErbB1 receptor trafficking
-
DOI 10.1038/sj.onc.1209976, PII 1209976
-
Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26(12):1693-701 (Pubitemid 46426203)
-
(2007)
Oncogene
, vol.26
, Issue.12
, pp. 1693-1701
-
-
Pochampalli, M.R.1
Bejjani, R.M.E.2
Schroeder, J.A.3
-
26
-
-
34547661985
-
L-BLP25: A peptide vaccine strategy in non small cell lung cancer
-
15 Pt 2
-
Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-4
-
(2007)
Clin. Cancer Res.
, vol.13
-
-
Sangha, R.1
Butts, C.2
-
28
-
-
0032127618
-
Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses
-
DOI 10.1021/bc970183n
-
Guan HH, Budzynski W, Koganty RR, et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-8 (Pubitemid 28338759)
-
(1998)
Bioconjugate Chemistry
, vol.9
, Issue.4
, pp. 451-458
-
-
Guan, H.H.1
Budzynski, W.2
Koganty, R.R.3
Krantz, M.J.4
Reddish, M.A.5
Rogers, J.A.6
Longenecker, B.M.7
Samuel, J.8
-
29
-
-
79959880112
-
L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study
-
Suppl: abstract e13153
-
Ohyanagi F, Horai T, Sekine I, et al. L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study. J Clin Oncol 2010;28(Suppl):abstract e13153
-
(2010)
J. Clin. Oncol.
, vol.28
-
-
Ohyanagi, F.1
Horai, T.2
Sekine, I.3
-
30
-
-
27244449289
-
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
-
DOI 10.1200/JCO.2005.13.011
-
Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81 (Pubitemid 46190262)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.27
, pp. 6674-6681
-
-
Butts, C.1
Murray, N.2
Maksymiuk, A.3
Goss, G.4
Marshall, E.5
Soulieres, D.6
Cormier, Y.7
Ellis, P.8
Price, A.9
Sawhney, R.10
Davis, M.11
Mansi, J.12
Smith, C.13
Vergidis, D.14
Ellis, P.15
MacNeil, M.16
Palmer, M.17
-
31
-
-
0031710507
-
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
-
DOI 10.1007/s002620050498
-
Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12 (Pubitemid 28430525)
-
(1998)
Cancer Immunology Immunotherapy
, vol.47
, Issue.1
, pp. 1-12
-
-
Bass, K.K.1
Mastrangelo, M.J.2
-
32
-
-
0029787977
-
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
-
MacLean GD, Miles DW, Rubens RD, et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-16 (Pubitemid 26313521)
-
(1996)
Journal of Immunotherapy
, vol.19
, Issue.4
, pp. 309-316
-
-
MacLean, G.D.1
Miles, D.W.2
Rubens, R.D.3
Reddish, M.A.4
Longenecker, B.M.5
-
33
-
-
65349149403
-
A multi-centre phase IIB randomized controlled study of BLP25liposome vaccine L-BLP25 or stimuvax for active specific immunotherapy of non-small cell lung cancer NSCLC: Updated survival analysis
-
abstract B1-01
-
Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis [abstract B1-01]. J Thorac Oncol 2007;2:S322-3
-
(2007)
J. Thorac. Oncol.
, vol.2
-
-
Butts, C.1
Maksymiuk, A.2
Goss, G.3
-
34
-
-
78649235731
-
A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer
-
Butts C, Murray RN, Smith CJ, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-Small-cell lung cancer. Clin Lung Cancer 2010;11:391-5
-
(2010)
Clin. Lung Cancer
, vol.11
, pp. 391-395
-
-
Butts, C.1
Murray, R.N.2
Smith, C.J.3
-
39
-
-
77953393492
-
Long-term safety of BLP25 liposome vaccine L-BLP25 in patients pts with stage IIIB/IV non-small cell lung cancer NSCLC
-
abstract 3055
-
Butts C, Anderson H, Maksymiuk A, et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S):abstract 3055
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.15 S
-
-
Butts, C.1
Anderson, H.2
Maksymiuk, A.3
-
40
-
-
79959900847
-
A multi-centre open-label study to assess the safety of stimuvax BLP25 liposome vaccine or L-BLP25 in non-small cell lung cancer NSCLC patients pts with unresectable stage III disease ASCO annual meeting proceedings part I
-
abstract 3075
-
Soulieres D, Smith C, Ellis PM, et al. A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):abstract 3075
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18 S
-
-
Soulieres, D.1
Smith, C.2
Ellis, P.M.3
|